EPISODE · Jun 10, 2024 · 12 MIN
ASCO 2024 Plenary: LAURA Trial in Unresectable Stage III EGFRm NSCLC
from Two Onc Docs
This week’s episode will be discussing updates from the ASCO 2024 annual meeting starting with the practice changing LAURA trial: Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III epidermal growth factor receptor-mutated NSCLC: Primary results of the phase 3 LAURA study presented by Dr. Ramalingam.
Embed this episode
NOW PLAYING
ASCO 2024 Plenary: LAURA Trial in Unresectable Stage III EGFRm NSCLC
0:00
12:15
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Two Onc Docs?
This episode is 12 minutes long.
When was this Two Onc Docs episode published?
This episode was published on June 10, 2024.
Can I download this Two Onc Docs episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!